Phuturdex › Drugs › Alrizomadlin
Drugs in development · updated 11 November 2026
Alrizomadlin: clinical trials and development status
Other names and codes: APG-115
As of 11 November 2026 Alrizomadlin is in 5 active clinical trials (recruiting or ongoing, phases I–III) for 8 diseases. The most advanced phase is II.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Adenoid cystic carcinoma | I–II | 1 | NCT03781986 |
| Liposarcoma | I–II | 1 | NCT04785196 |
| Neuroblastoma | I–II | 1 | NCT05701306 |
| Neurofibromatosis 1 | I–II | 1 | NCT06735820 |
| Neurofibrosarcoma | I–II | 1 | NCT06735820 |
| Non-Hodgkin lymphoma | II | 1 | NCT04496349 |
| Salivary gland neoplasm | I–II | 1 | NCT03781986 |
| T-cell prolymphocytic leukemia | II | 1 | NCT04496349 |
Everything on Alrizomadlin
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.